

Special Issue

Diagnosis, Pathogenesis and Treatment of TAFRO Syndrome

Message from the Guest Editors

This Special Issue, "Diagnosis, Pathogenesis and Treatment of TAFRO syndrome", will mainly focus on the novel severe hyper-inflammatory disorder, called TAFRO syndrome, which was first reported in Japan in 2010. Because lymph node histology is similar in patients with TAFRO syndrome and Castleman disease, TAFRO syndrome is described as a related disorder of Castleman disease; however, the two conditions are markedly different clinically. Cases with hyper-inflammation syndrome, such as TAFRO syndrome, require intensive therapeutic strategy. Further understanding of TAFRO syndrome requires the identification of novel disease-specific biomarkers. For this Special Issue, we invite authors to submit original research and review articles that focus on the diagnosis, pathogenesis and therapeutic potential of TAFRO syndrome. Potential topics include, but are not limited to, the following:

- ☒ Clinical and Pathological diagnosis;
- ☒ Relationship and differentiation with iMCD, IPL, POEMS syndrome, malignancies, infections and collagen-vascular disorders;
- ☒ Cytokine, chemokine and other factors;
- ☒ Therapeutic trials and experiences.

Guest Editors

Prof. Dr. Yasufumi Masaki

Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan

Prof. Dr. Sadao Aoki

Hematology Division, Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, Japan

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182881

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).